Cardiovascular Event Articles & Analysis
39 news found
Unlike traditional diabetes medications, Semaglutide has been shown to improve glycemic control, promote weight loss, and reduce the risk of cardiovascular events in individuals with type 2 diabetes. "The introduction of Semaglutide reinforces our commitment to delivering innovative solutions that address the growing challenges of type 2 diabetes," said the ...
“Despite progress in risk reduction in type 2 diabetes, chronic kidney disease in type 1 diabetes remains understudied, leaving a huge unmet need to reduce the risks of end-stage kidney disease and cardiovascular events. New strategies are needed to slow the rate of decline in kidney function, which is why this important study comes as welcome news for ...
ByBayer AG
The positive data from FIGARO-DKD demonstrated that finerenone significantly reduced the risk of cardiovascular events in adult patients with CKD and T2D versus placebo. “Patients with chronic kidney disease are faced with an increased risk of cardiovascular events,” said Professor Peter Rossing, Head of ...
ByBayer AG
The study demonstrated that finerenone reduced the risk of cardiovascular events in a broad population of patients with stages 1-4 CKD and T2D. ...
ByBayer AG
” Over the last two decades, disease activity in rheumatoid arthritis (RA) has improved, yet fatigue and pain continue to hinder patients’ quality of life (QOL), and ability to function.2,3 Less than 30% of patients are satisfied with their pain levels and 40-80% of RA patients are affected by fatigue.4,5 Pain and fatigue have negative impacts on mental and physical QOL, including ...
The Premier Event for The Cardiovascular Industry’s Leading Network of Executives and Clinicians – Sharing Best Practices, Guidance and Resources to Dramatically Improve Their Business and Patient-Care Outcomes Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting for the ...
The prespecified FIDELITY pooled analysis investigated the efficacy and safety of finerenone across the spectrum of patients with CKD in T2D in reducing the risk of chronic kidney disease progression as well as fatal and nonfatal CV events and provided insights into the relationship between CKD stage (based on baseline Kidney Disease: Improving Global Outcomes – KDIGO ...
ByBayer AG
The positive data from the pivotal Phase III FIGARO-DKD study demonstrated that finerenone significantly reduced the risk of cardiovascular events in adult patients with CKD and T2D. Results from the trial were presented at ESC Congress 2021, and simultaneously published in the New England Journal of Medicine. ...
ByBayer AG
The prespecified FIDELITY pooled analysis investigated the efficacy and safety of finerenone across the spectrum of patients with CKD in T2D in reducing the risk of chronic kidney disease progression as well as fatal and nonfatal CV events and insights into the relationship between CKD stage (based on baseline KDIGO [Kidney Disease: Improving Global Outcomes] risk categories) and ...
ByBayer AG
It´s the first trial to demonstrate the benefits of dual pathway inhibition - with the anticoagulant Xarelto in combination with the antiplatelet aspirin - in these PAD patients at high risk of major adverse cardiovascular events (MACE) and especially major adverse limb events (MALE). ...
ByBayer AG
In the BeAT-HF Study, patients who had Barostim implanted were able to walk further in a 6-minute hall walk test, have a higher quality of life and appeared to have a reduction in the rate of serious cardiovascular events, including arrythmias, compared to the control group. ...
ByCVRx
“We look forward to providing patients and physicians in Japan with a new treatment option to delay kidney disease progression and reduce the risk of cardiovascular events. The approval of finerenone offers a new path to protect patients from further kidney and cardiovascular damage through addressing MR overactivation, a key driver of CKD ...
ByBayer AG
“Even when blood glucose levels and blood pressure are well-controlled, the risk of chronic kidney disease progression and cardiovascular events remains high in these patients,” said Professor Peter Rossing, Head of Complications Research at the Steno Diabetes Center Copenhagen. ...
ByBayer AG
AEs of special interest in patients treated with AR pathway inhibitors for prostate cancer such as fatigue, falls, fractures, mental impairment, and cardiovascular events were similar between study arms. About the ARASENS Trial The ARASENS trial is a randomized, Phase III, multi-center, double-blind, placebo-controlled trial which was prospectively designed to ...
ByBayer AG
– February 15, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced completion of enrollment in the BIOADAPTOR randomized controlled trial (RCT). ...
Levels < 86 ng/mL included among other things a lower risk of cardiovascular events (such as ventricular tachycardia, ventricular fibrillation, sudden cardiac death), improved cardiac function, and low fatty infiltration in the heart. ...
These patients have a critical need for treatment options that can delay kidney disease progression and reduce the risk of cardiovascular events,” said Professor Peter Rossing, Head of Complications Research at the Steno Diabetes Center Copenhagen. ...
ByBayer AG
New Phase III study VICTOR will assess vericiguat efficacy and safety in patients who have not had a recent worsening heart failure event / VICTOR expands upon the Phase III VICTORIA study, providing further insight into the use of vericiguat in a broader range of patients with chronic heart failure with reduced ejection fraction Bayer and its development partner MSD (a ...
ByBayer AG
The primary objective of the study is to demonstrate superiority of finerenone over placebo in reducing the rate of the composite endpoint of cardiovascular death and total (first and recurrent) heart failure (HF) events (defined as hospitalizations for HF or urgent HF visits). ...
ByBayer AG
Reported in The Journal of Thoracic and Cardiovascular Surgery, patients who received the transplantation were more likely to successfully separate from ECMO, had a shorter median time to functional recovery after revascularization, and experienced fewer cardiovascular events. ...